The Ministry of health of the USA has published the draft recommendations addressed to the food industry, a relatively gradual decline in the amount of salt in prepared foods. The document drew criticism from both the supporters of such measures, and their opponents.
In the United States began a new stage in the struggle to reduce the amount of salt in food: Management of quality control food and drug administration (FDA) has issued for public discussion a draft resolution, which, if final approval must ensure the gradual reduction of salt content in prepared foods.
The draft recommendation contains a fairly detailed list of product categories the total number of 150, the salt content of which should be reduced from muesli to pizza and slicing meat products.
The appearance of the recommendations, which aim to convince the owners of the enterprises of the food industry to voluntarily reduce the content of sodium chloride in their products due to the fact that, according to the FDA, U.S. residents every day is still consume too much salt.
Currently, this consumption in the country is about 3.4 g per day, which is almost a third higher than scientists recommended dose of 2.3 g.
Representatives of public organizations fighting for the health of Americans, say the piecemeal method of solving problems proposed by the FDA, although welcomed the publication of the recommendations (which the Ministry of health, the US promised to prepare another in the spring of 2010).
The criticism is the fact that the norms of the salt content in many food products are only Advisory and not mandatory.
On the other hand, representatives of the food industry welcomed the publication of the recommendations, too, without much enthusiasm, as they fear that reducing the amount of salt in popular foods will change their flavor and reduce consumer demand.
However, the analysis that was performed by experts from the FDA, showed that nationwide reduction in salt consumption by 40% over the next 10 years would reduce mortality from cardiovascular disease by 500 000 cases and reduce costs for treatment of such diseases by almost 100 billion US dollars.